

SUPPLEMENTAL MATERIAL

Deep Mining of Oxysterols and Cholestenic Acids in Human Plasma and Cerebrospinal Fluid: Quantification using Isotope Dilution Mass Spectrometry

Eylan Yutuc¹, Alison L. Dickson¹, Manuela Pacciarini¹, Lauren Griffiths¹, Paul R.S. Baker², Lisa Connell², Anders Öhman³, Lars Forsgren⁴, Miles Trupp⁴, Sílvia Vilarinho⁵, Youssef Khalil⁶, Peter T. Clayton⁶, Sinan Sari⁷, Buket Dalgic⁷, Philip Höflinger⁸, Ludger Schöls^{8,9}, William J. Griffiths¹ and Yuqin Wang¹

¹Swansea University Medical School, ILS1 Building, Singleton Park, Swansea SA2 8PP, Wales, UK

²Avanti Polar Lipids Inc, Alabaster, AL, USA

³Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden

⁴Department of Clinical Science, Neurosciences, Umeå University, SE-901 85 Umeå, Sweden

⁵Departments of Internal Medicine, Section of Digestive Diseases, and of Pathology, Yale University School of Medicine, New Haven, CT, USA

⁶Inborn Errors of Metabolism, Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK

⁷Department of Pediatrics, Division of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey

⁸Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

⁹German Center for Neurodegenerative Diseases (DZNE), Tübingen

Supplemental Information

Supplemental Methods

Flowchart 1. Schematic illustration of sample preparation. Single-phase liquid extraction is performed into ethanol containing internal standards in the presence or absence of 0.35 M KOH.

Flowchart 2. Different protocols for single-phase liquid extraction.

Flowchart 3. Flowchart showing sterol identification and quantification routine.

Supplemental Figures and Tables

Figure S1. *Syn* (*Z*) and *anti* (*E*) conformers of the GP-derivative exemplified for 24S-HC. Also shown are 3D minimised energy structures (Chem 3D Pro). MS² fragmentation results in loss of the pyridine (Py) group with the formation of the [M-Py]⁺ fragment ion.

Figure S2. LC-MS separation of GP-derivatised monohydroxycholesterols (HC). (A) Mass spectrometric peaks at *m/z* 546.48 corresponding to the [M]⁺ ion of [²H₇]24S-HC (upper panel); the [M+1]⁺ ion of [²H₆]26-HC (lower panel); and unresolved [M]⁺ ion of [²H₇]24R-HC and the [M+1]⁺ ion of [²H₆]26-HC (central panel). The structure of the [M+1]⁺ ion of [²H₆]26-HC is arbitrarily drawn with a ¹³C at C-21. (B) Upper panel, TIC 534.4→455.4 for monohydroxycholestenones in plasma. Lower panel TICs 541.5→462.4 for [²H₇]-labelled monohydroxycholesterols.

Figure S3. MS³ fragmentation of GP-derivatised monohydroxycholesterols in plasma. MS³ ([M]⁺→[M-Py]⁺) spectra of (A) 24S-HC; (B) 24R-HC; (C) [²H₇]24S-HC; (D) [²H₇]24R-HC; (E) 25-HC; (F) [²H₆]25-HC; (G) (25R)26-HC; (H) [²H₆](25R)26-HC; (I) [²H₇]22R-HC; (J) 22S-HC; (K) [²H₇]22S-HC. The formation of key fragment ions is illustrated in Figure S4A-D.

Figure S4. Key fragmentation routes in the MSⁿ spectra of GP-derivatised oxysterols. Mechanisms of side-chain cleavage are indicated by purple arrows. (A) 24R/S-HC and [²H₆]24R/S-HC; (B) 25-HC and [²H₆]25-HC; (C) (25R)26-HC and [²H₆](25R)26-HC; (D) 22R/S-HC and [²H₇]22R/S-HC; (E) 7-HC and [²H₇]7-HC; (F) 6β-HC and [²H₇]6β-HC; (G) 7-OC and [²H₇]7-OC; (H) 12α-HC; (I) 7α,25-diHC and [²H₆]7α,25-diHC; (J) 7α,(25R/S)26-diHC and [²H₆]7α,(25R/S)26-diHC; (K) 7α,12α-diHC; (L) 3β,7-diHCA(25R/S) and [²H₃]3β,7-diHCA(25R/S); (M) 25-D₃ and [²H₆]25-D₃; (N) 3βH-Δ⁵-BA and 3β,7-diH-Δ⁵-BA; (O) 3β-HCA; (P) 3β,7α,24-triHCA; (Q) 3β,7α,25-triHCA; (R) 3β,7α,12α-triHCA; (S) 3β,25-diHCA; (T) 3β,27-diHCA; (U) 3β,22,25-triHCA-24O; (V) 3β,22-diHCA-24O.

Figure S5. MS³ fragmentation of GP-derivatised monohydroxycholesterols and monohydroxycholestenones in plasma. MS³ ([M]⁺→[M-Py]⁺) spectra of (A) 7β-HC; (B) [²H₇]7β-HC; (C) 7α-HC; (D) [²H₇]7α-HC; (E) 6β-HC (5α,6β-diHC-18), generated from the acid catalysed dehydration of 5α,6β-diHC; (F) [²H₇]6β-HC ([²H₇]5α,6β-18) generated from the acid catalysed dehydration of [²H₇]5α,6β-diHC; (G) 7-OC; (H) [²H₇]7-OC; (I) 7α-HCO; (J) [²H₇]7α-HCO; (K) 12α-HC (no authentic standard). The formation of key fragment ions is illustrated in Figure S4E-H.

Figure S6. LC-MS separation of GP-derivatised dihydroxycholesterols, dihydroxycholestenones (diHCO), dihydroxycholestenonic (diHCA) and hydroxyoxocholestenonic (H,O-CA) acids. (A) RIC for the [M]⁺ ions of (upper panel) 7α,25-diHC + 7α,25-diHCO and 7α,(25R/S)26-diHC + 7α,(25R/S)26-diHCO (555.4317 ± 5 ppm) found in plasma and (lower panel) [²H₆]7α,25-diHC and [²H₆]7α,(25R/S)26-diHC (561.4694 ± 5 ppm) over a 37 min gradient. (B) RIC of the [M]⁺ ions of dihydroxycholestenones (550.4003 ± 5 ppm) found in plasma. Upper panel 37 min gradient, lower panel 17 min gradient. (C) RIC for the [M]⁺ ions of (upper panel) 7αH,3O-CA(25R/S) (564.3796 ± 5 ppm) found in plasma and (lower panel) [²H₃]7αH,3O-CA(25R/S) (567.3984 ± 5 ppm) over a 37 min gradient. (D) RIC for the [M]⁺

ions of (upper panel) $7\alpha\text{H},3\text{O-CA}(25\text{R}/\text{S}) + 3\beta,7\alpha\text{-diHCA}(25\text{R}/\text{S})$ (569.4110 ± 5 ppm) found in plasma and (lower panel) $[^2\text{H}_3]7\alpha\text{H},3\text{O-CA}(25\text{R}/\text{S})$ (572.4298 ± 5 ppm) over a 37 min gradient. Coloured dashed lines indicate the coincidence of oxysterols between chromatograms.

Figure S7. MS^3 fragmentation of GP-derivatised dihydroxycholesterols (diHC) and dihydroxycholestenones (diHCO) in plasma. MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py}]^+ \rightarrow$) spectra of (A) $7\alpha,25\text{-diHC} + 7\alpha,25\text{-diHCO}$; (B) $[^2\text{H}_6]7\alpha,25\text{-diHC}$; (C) $7\alpha,(25\text{S})26\text{-diHC} + 7\alpha,(25\text{S})26\text{-diHCO}$; (D) $[^2\text{H}_6]7\alpha,(25\text{S})26\text{-diHC}$; (E) $7\alpha,(25\text{R})26\text{-diHC} + 7\alpha\text{H},(25\text{R})26\text{-diHCO}$; (F) $[^2\text{H}_6]7\alpha,(25\text{R})26\text{-diHC}$; (G) $7\alpha,25\text{-diHCO}$; (H) $7\alpha,(25\text{R})26\text{-diHCO}$; (I) $7\alpha,12\alpha\text{-diHC}$. The formation of key fragment ions is illustrated in Figure S4I – S4K.

Figure S8. MS^3 fragmentation of GP-derivatised dihydroxycholestenic (diHCA) and hydroxyoxocholestenic (H,O-CA) acids in plasma. MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py}]^+ \rightarrow$) spectra of (A) $3\beta,7\beta\text{-diHCA}(25\text{R})$; (B) $3\beta,7\alpha\text{-diHCA}(25\text{S}) + 7\alpha\text{H},3\text{O-CA}(25\text{S})$; (C) $[^2\text{H}_3]3\beta,7\alpha\text{-diHCA}(25\text{S})$; (D) $3\beta,7\alpha\text{-diHCA}(25\text{R}) + 7\alpha\text{H},3\text{O-CA}(25\text{R})$; (E) $[^2\text{H}_3]3\beta,7\alpha\text{-diHCA}(25\text{R})$; (F) $7\alpha\text{H},3\text{O-CA}(25\text{S})$; (G) $7\alpha\text{H},3\text{O-CA}(25\text{R})$; (H) $[^2\text{H}_3]7\alpha\text{H},3\text{O-CA}(25\text{R})$. The formation of key fragment ions is illustrated in Figure S4L.

Figure S9. LC-MS(MS^3) of cholesterol and other lipophilic sterols in plasma. (A) RIC for the $[\text{M}]^+$ ions of cholesterol (upper panel, 523.4419 ± 5 ppm), $[^2\text{H}_7]\text{cholesterol}$ (central panel, 530.4858 ± 5 ppm) and isomers of cholestadien- $3\beta\text{-ol}$ (lower panel 521.4262 ± 5 ppm). MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py}]^+ \rightarrow$) spectra of (B) cholesterol, (C) $[^2\text{H}_7]\text{cholesterol}$, (D) desmosterol (24-DHC) and (E) 8(9)-dehydrocholesterol (8-DHC). The formation of key fragment ions is illustrated in (F – H).

Figure S10. LC-MS separation of GP-derivatised 25-hydroxyvitamin D_3 and sterol-acids in plasma. (A) RIC for the $[\text{M}]^+$ ions of 25- D_3 (537.4211 ± 5 ppm, upper panel) and $[^2\text{H}_6]25\text{-D}_3$ (543.4588 ± 5 ppm, lower panel); (B) $3\beta\text{H-}\Delta^5\text{-BA}$ (511.3691 ± 5 ppm); (C) $3\beta,7\beta\text{-diH-}\Delta^5\text{-BA}$ and $3\alpha,7\alpha\text{-diH-}\Delta^5\text{-BA} + 7\alpha\text{H},3\text{O-}\Delta^4\text{-BA}$ (527.3640 ± 5 ppm, upper panel); $7\alpha\text{H},3\text{O-}\Delta^4\text{-BA}$ (522.3326 ± 5 ppm, lower panel,); (D) $3\beta\text{-HCA} + 3\text{O-CA}$ (553.4161 ± 5 ppm, upper panel,); 3O-CA (548.3847 ± 5 ppm, lower panel,); (E - H) $3\beta,7\alpha,24\text{-triHCA} + 7\alpha,24\text{-diH},3\text{O-CA}$, $3\beta,7\alpha,25\text{-triHCA} + 7\alpha,25\text{-diH},3\text{O-CA}$ and $3\beta,7\alpha,12\alpha\text{-triHCA} + 7\alpha,12\alpha\text{-diH},3\text{O-CA}$ (585.4059 ± 5 ppm, upper panels); (E) Lower panel, $7\alpha,24\text{-diH},3\text{O-CA}$, $7\alpha,25\text{-diH},3\text{O-CA}$ and $7\alpha,12\alpha\text{-diH},3\text{O-CA}$ (580.3739 ± 5 ppm); (F – H) Lower panels show MRM chromatograms targeting (F) $3\beta,7\alpha,24\text{-triHCA} + 7\alpha,24\text{-diH},3\text{O-CA}$; (G) $3\beta,7\alpha,25\text{-triHCA} + 7\alpha,25\text{-diH},3\text{O-CA}$; (H) $3\beta,7\alpha,12\alpha\text{-triHCA}$ and $7\alpha,12\alpha\text{-diH},3\text{O-CA}$. Authentic standards are not available for $3\beta,7\alpha,12\alpha\text{-triHCA}$ and $7\alpha,12\alpha\text{-diH},3\text{O-CA}$. Coloured dashed lines indicate the coincidence of oxysterols between chromatograms. MS^3 spectra are presented in Figures S11 & S12.

Figure S11. MS^3 fragmentation of GP-derivatised 25-hydroxyvitamin D_3 and sterol acids in plasma. MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py-H}_2\text{O}]^+ \rightarrow$) spectra of (A) 25- D_3 and (B) $[^2\text{H}_6]25\text{-D}_3$. MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py}]^+ \rightarrow$) spectra of (C) $3\beta\text{H-}\Delta^5\text{-BA}$; (D) $3\beta,7\beta\text{-diH-}\Delta^5\text{-BA}$; (E) $3\beta,7\alpha\text{-diH-}\Delta^5\text{-BA} + 7\alpha\text{H},3\text{O-}\Delta^4\text{-BA}$; (F) $7\alpha\text{H},3\text{O-}\Delta^4\text{-BA}$; (G) $3\beta\text{-HCA} + 3\text{O-CA}$; (H) 3O-CA . The formation of key fragment ions is illustrated in Figure S4M-O.

Figure S12. MS^3 fragmentation of GP-derivatised of trihydroxycholestenic (triHCA) and dihydroxy-3-oxocholestenic acids (diH,3O-CA) in plasma. MS^3 ($[\text{M}]^+ \rightarrow [\text{M-Py}]^+ \rightarrow$) spectra of (A) $3\beta,7\alpha,24\text{-triHCA} + 7\alpha,24\text{-diH},3\text{O-CA}$; (B) $3\beta,7\alpha,25\text{-triHCA} + 7\alpha,25\text{-diH},3\text{O-CA}$; (C) $3\beta,7\alpha,12\alpha\text{-triHCA} + 7\alpha,12\alpha\text{-diH},3\text{O-CA}$ (no authentic standard). The formation of key fragment ions is illustrated in Figure S4P-R.

Figure S13. MS^3 fragmentation of GP-derivatised oxysterols in plasma. MS^3 spectra of the postulated structures (A) $3\beta,25\text{-diHCA}$ or $3\beta,25,x\text{-trihydroxycholest-5-en-y-one}$ (no authentic standards available); (B) $3\beta,27\text{-diHCA}$ or $3\beta,27,x\text{-trihydroxycholest-5-en-y-one}$ (no authentic standards available); (C) $3\beta,x\text{-diHCA}$ or $3\beta,x,y\text{-trihydroxycholest-5-en-z-one}$ (no authentic standards available); (D) $3\beta,22,25\text{-trihydroxycholest-5-en-24-one}$ or $3\beta,x\text{-diHCA}$ (no authentic standard); (E) $3\beta,22\text{-dihydroxycholest-5-en-24-one}$ or $3\beta,20\text{-dihydroxycholest-5-en-22-one}$ (no authentic standard); (F) $7\alpha,x\text{-diH},3\text{O-CA}$ (no

authentic standard). The more likely structures are given in *italics*. The formation of key fragment ions is illustrated in Figure S4S-V.

Figure S14. MS³ fragmentation of GP-derivatised of trihydroxycholestenoic (triHCA) and dihydroxy-3-oxocholestenoic acids (diH,3O-CA) in CSF. MS³ ([M]⁺→[M-Py]⁺→) spectra of (A) 3β,7α,24-triHCA + 7α,24-diH,3O-CA; (B) 3β,7α,25-triHCA + 7α,25-diH,3O-CA; (C) 3β,7α,12α-triHCA + 7α,12α-diH,3O-CA (no authentic standard) and (D) 3β,7α,x-triHCA + 7α,x-diH,3O-CA. The formation of key fragment ions is illustrated in Figure S4P-R.


Table S1. Systematic and common names of sterols including oxysterols and sterol-acids identified or partially identified in the current study. Supplier of reference standards are indicated when available.

Table S2. Figures of merits when varying amount of OxysterolSPLASH at a plasma volume of 100 μL.

Table S3. Figures of merit revealed by standards additions to (A) 100 μL of plasma using 50 μL of OxysterolSPLASH and (B) 100 μL CSF using 20 μL of OxysterolSPLASH.



Table S4. Diagnostic fragment ions and simple rules for structure determination of GP-derivatised sterols.

Flowchart 1




Schematic illustration of sample preparation. Single-phase liquid extraction is performed into ethanol containing internal standards in the presence or absence of 0.35 M KOH


Flowchart 2. Different protocols for single-phase liquid extraction.




Flowchart 3





Flowchart showing sterol identification and quantification routine





Chemical Formula: $C_{34}H_{47}D_5N_3O_2^+$
Exact Mass: 539.4368



Chemical Formula: $C_{34}H_{47}D_5N_3O_2^+$
Exact Mass: 539.4368





MS^2




Chemical Formula: $C_{29}H_{47}N_2O_2^+$
Exact Mass: 455.3632

$[M-Py]^+$






NL: 1.36E5
EY_191014_100uL-NIST-
QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr
1B=GPd0_s2_03#3073 RT: 14.89
AV: 1 F: FTMS + p ESI Full ms
[400.00-610.00]




NL: 2.16E5
EY_191014_100uL-NIST-
QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr
1B=GPd0_s2_03#3589 RT: 17.40
AV: 1 F: FTMS + p ESI Full ms
[400.00-610.00]




NL: 1.77E5
EY_191014_100uL-NIST-
QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr
1B=GPd0_s2_03#3601 RT: 17.46
AV: 1 F: FTMS + p ESI Full ms
[400.00-610.00]


RT: 0.00 - 17.02





NL: 2.34E4
TIC F: ITMS + c ESI Full ms3
534.41@cid30.00 455.36@cid35.00
[125.00-550.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=
GPd0_s2_02




NL: 3.00E5
TIC F: ITMS + c ESI Full ms3
541.45@cid30.00 462.41@cid35.00
[125.00-555.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=
GPd0_s2_02













EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]

15.94 AV: 1 NL: 2.08E3












EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:44:12
100uL NIST (2018) + 100uL OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]


7.86 AV: 1 NL: 1.28E3







MS³: 545→461→
18.35 min (37 min gradient)
[²H₆](25R)26-HC



Chemical Formula: C₃₄H₄₁D₁₁N₃O₂⁺
Exact Mass: 545.4744




Figure S4A




Figure S4B




Figure S4C




Figure 4D




Figure S4E




Figure S4F




Figure S4G




Figure S4I




Figure S4J





Figure S4K






Figure S4M




Figure S4N upper




Figure S4N lower




Figure S40




Figure 4P




Figure S4R




Figure S4T




Figure S4U







Figure S4V





EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]

9.13 AV: 1 NL: 5.83E2











EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 539.44@cid30.00 455.36@cid35.00 [125.00-550.00]

9.97 AV: 1 NL: 1.11E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 546.48@cid30.00 462.41@cid35.00 [125.00-555.00]

9.93 AV: 1 NL: 2.25E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_F
F: ITMS + c ESI Full ms3 534.41@cid30.00 455.36@cid35.00 [125.00-55

T: 9.37 AV: 1 NL: 1.07E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_F
F: ITMS + c ESI Full ms3 541.45@cid30.00 462.41@cid35.00 [125.00-55

T: 9.33 AV: 1 NL: 2.41E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100uL OxysterolSPLASH + 10ng 22S-HCO-D7 + 20
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_F
F: ITMS + c ESI Full ms3 534.41@cid30.00 455.36@cid35.00 [125.00-55


T: 9.69 AV: 1 NL: 9.01E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 02:23:26
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_F
F: ITMS + c ESI Full ms3 541.45@cid30.00 462.41@cid35.00 [125.00-55

T: 9.65 AV: 1 NL: 6.05E3






RT: 0.00 - 37.01



NL: 3.39E4
m/z= 555.4289-555.4345 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_03


RIC: 555.4317



NL: 6.79E3
m/z= 561.4666-561.4722 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_03

RIC: 561.4694


RT: 0.00 - 37.01



NL: 2.77E4
m/z= 550.3975-550.4031 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_03

RIC: 550.4003


RT: 0.00 - 17.00



NL: 3.82E4
m/z= 550.3975-550.4031 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_04

RIC: 550.4003

RT: 0.00 - 37.01



NL: 2.51E5
 m/z= 564.3768-564.3824 F: FTMS +
 p ESI Full ms [400.00-610.00] MS
 EY_191014_100uL-NIST-QC_100uL-
 OxySplash_rep2of5_Fr1A=GPd5_Fr1
 B=GPd0_s2_03

RIC: 564.3796



NL: 1.23E5
 m/z= 567.3956-567.4012 F: FTMS +
 p ESI Full ms [400.00-610.00] MS
 EY_191014_100uL-NIST-QC_100uL-
 OxySplash_rep2of5_Fr1A=GPd5_Fr1
 B=GPd0_s2_03

RIC: 567.3984

RT: 0.00 - 37.01

NL: 3.58E5
m/z= 569.4082-569.4138 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_03



RIC: 569.4110



Chemical Formula: C₃₄H₄₅D₅N₃O₄⁺
Exact Mass: 569.4110

NL: 1.28E5
m/z= 572.4269-572.4327 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_03


RIC: 572.4298



Chemical Formula: C₃₄H₄₂D₈N₃O₄⁺
Exact Mass: 572.4298


EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]

5.03 AV: 1 NL: 2.77E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 561.47@cid30.00 477.40@cid35.00 [130.00-570.00]


4.97 AV: 1 NL: 1.29E3



EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]


5.43 AV: 1 NL: 5.27E2






EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]


5.64 AV: 1 NL: 3.64E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 561.47@cid30.00 477.40@cid35.00 [130.00-570.00]

5.59 AV: 1 NL: 4.27E2









EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:26:25
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 555.43@cid30.00 471.36@cid35.00 [125.00-560.00]

8.41 AV: 1 NL: 2.53E2




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]

.29 AV: 1 NL: 1.23E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]

5.13 AV: 1 NL: 7.92E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 572.43@cid30.00 488.36@cid35.00 [130.00-580.00]

5.11 AV: 1 NL: 9.87E3




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 569.41@cid30.00 485.34@cid35.00 [130.00-575.00]


5.36 AV: 1 NL: 3.45E4




EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 572.43@cid30.00 488.36@cid35.00 [130.00-580.00]

5.30 AV: 1 NL: 1.20E4









EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 03:47:11
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 567.40@cid30.00 488.36@cid35.00 [130.00-580.00]


5.30 AV: 1 NL: 1.21E4




EY_200610_190628_NIST-QC_OxySplash_+... 06/10/20 17:30:32
 100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d
 RT: 0.00 - 17.02




NL: 3.83E7
 m/z= 523.4393-523.4445 F: FTMS + p
 ESI Full ms [400.00-610.00] MS
 EY_200610_190628_NIST-
 QC_OxySplash_+22S-HCO-d7_+
 Chol-
 d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]
 _01



NL: 1.94E7
 m/z= 530.4831-530.4885 F: FTMS + p
 ESI Full ms [400.00-610.00] MS
 EY_200610_190628_NIST-
 QC_OxySplash_+22S-HCO-d7_+
 Chol-
 d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]
 _01




NL: 3.43E4
 m/z= 521.4236-521.4288 F: FTMS + p
 ESI Full ms [400.00-610.00] MS
 EY_200610_190628_NIST-
 QC_OxySplash_+22S-HCO-d7_+
 Chol-
 d7_Fr3A=GPd5_Fr3B=GPd0_1in100_s3]
 _01




EY_200610_190628_NIST-QC_OxySplash_+... 06/10/20 17:30:32
100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7
EY_200610_190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr
F: ITMS + c ESI Full ms3 530.49@cid30.00 446.41@cid35.00 [120.00-53

00_s3j_01 #2368 RT: 10.97 AV: 1 NL: 1.37E6




EY_200610_190628_NIST-QC_OxySplash_+... 06/10/20 17:50:25
100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (α
EY_200610_190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A
F: ITMS + c ESI Full ms3 521.43@cid30.00 437.35@cid35.00 [120.00-530.00]


_s3]_02 #2232 RT: 10.36 AV: 1 NL: 1.14E3





EY_200610_190628_NIST-QC_OxySplash_+... 06/10/20 17:50:25
100uL NIST (2018) + 100uL splash + 20ng 22S-HCO-D7 + 20ug Chol-d7 (α
EY_200610_190628_NIST-QC_OxySplash_+22S-HCO-d7_+Chol-d7_Fr3A
F: ITMS + c ESI Full ms3 521.43@cid30.00 437.35@cid35.00 [120.00-530.00]

_s3]_02 #2328 RT: 10.76 AV: 1 NL: 2.80E3










S10A

EY_191014_100uL-NIST-QC_with_2017-Pro...
100uL NIST (2018) + 2017-Protocol-iSTDs (¿

10/16/19 13:46:25
1g 22S-HCO-D7 + 20ug Chol-D7(certified)


RT: 0.00 - 17.01



NL: 7.13E4
m/z= 537.4185-537.4239 F: FTMS + p
ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-
QC_with_2017-Protocol-
iSTDs_rep2of5_Fr1A=GPd5_Fr1B=GP
d0_s7_09

NL: 3.41E5
m/z= 543.4561-543.4615 F: FTMS + p
ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-
QC_with_2017-Protocol-
iSTDs_rep2of5_Fr1A=GPd5_Fr1B=GP
d0_s7_09


RT: 0.00 - 17.01



NL: 1.50E4
m/z= 511.3665-511.3717 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_11


RIC: 511.3691

RT: 0.00 - 17.00



NL: 4.95E4
m/z= 527.3614-527.3666 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_06


RIC: 527.3640



NL: 2.67E4
m/z= 522.3300-522.3352 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_06

RIC: 522.3326

RT: 0.00 - 17.00



NL: 8.56E5
m/z= 553.4133-553.4189 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_07

RIC: 553.4160


NL: 1.39E4
m/z= 548.3820-548.3874 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_07

RIC: 548.3847

7α,x-diH,3O-CA ← 3β,7α,12α-triHCA + 7α,12α-diH,3O-CA


3β,7α,24-triHCA +
7α,24-diH,3O-CA

3β,7α,25-triHCA +
7α,25-diH,3O-CA



NL: 1.24E4
m/z= 585.4030-585.4088 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_07

RIC: 585.4059



NL: 1.08E4
m/z= 580.3716-580.3774 F: FTMS +
p ESI Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1
B=GPd0_s2_07

RIC: 580.3739

S10F

EY_191014_100uL-NIST-QC_100uL-OxySpla...
100uL NIST (2018) + 100ul OxysterolSPLAS
RT: 0.00 - 17.00


10/15/19 04:28:42
µg Chol-D7(certified)

NL: 1.24E4

m/z= 585.4030-585.4088 F: FTMS + p ESI
Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07

RIC: 585.4059


3β,7α,24-triHCA + 7α,24-diH,3O-CA



NL: 1.58E2

m/z= 427.0000-427.7000 F: ITMS + c ESI Full
ms3 585.41@cid30.00 501.33@cid35.00
[135.00-590.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07


MRM: 585→501→427



EY_191014_100uL-NIST-QC_100uL-OxySpla...
100uL NIST (2018) + 100ul OxysterolSPLAS
RT: 0.00 - 17.00

10/15/19 04:28:42
µg Chol-D7(certified)

3β,7α,25-triHCA + 7α,25-diH,3O-CA




NL: 1.24E4

m/z= 585.4030-585.4088 F: FTMS + p ESI
Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07

RIC: 585.4059

← 3β,7α,25-triHCA + 7α,25-diH,3O-CA




NL: 3.66E2

m/z= 455.0000-455.7000 F: ITMS + c ESI Full
ms3 585.41@cid30.00 501.33@cid35.00
[135.00-590.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07

MRM: 585→501→455


RT: 0.00 - 17.00



NL: 1.24E4

m/z= 585.4030-585.4088 F: FTMS + p ESI
Full ms [400.00-610.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07

RIC: 585.4059



NL: 3.75E2


m/z= 422.0000-422.7000 F: ITMS + c ESI Full
ms3 585.41@cid30.00 501.33@cid35.00
[135.00-590.00] MS
EY_191014_100uL-NIST-QC_100uL-
OxySplash_rep2of5_Fr1A=GPd5_Fr1B=GPd0
_s2_07

MRM: 585→501→422

EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 05:10:14
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 537.42@cid30.00 435.34@cid35.00 [115.00-545.00]


8.19 AV: 1 NL: 4.20E3


**MS³: 537→435→
8.19 min (17 min gradient)
25-D₃**



EY_191014_100uL-NIST-QC_with_2017-Pro... 10/16/19 13:46:25
100uL NIST (2018) + 2017-Protocol-iSTDs (20ng 24RS-HC-d6-cert) + 10ng
EY_191014_100uL-NIST-QC_with_2017-Protocol-iSTDs_rep2of5_Fr1A=GF
F: ITMS + c ESI Full ms3 543.46@cid30.00 441.37@cid35.00 [120.00-550.00]


7(certified)
50 RT: 8.19 AV: 1 NL: 1.28E4






EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:07:57
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 527.36@cid30.00 443.29@cid35.00 [120.00-535.00]


.12 AV: 1 NL: 1.08E3





EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:07:57
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 527.36@cid30.00 443.29@cid35.00 [120.00-535.00]

.62 AV: 1 NL: 3.59E3













EY_191014_100uL-NIST-QC_100uL-OxySpla... 10/15/19 04:28:42
100uL NIST (2018) + 100ul OxysterolSPLASH + 10ng 22S-HCO-D7 + 20ug
EY_191014_100uL-NIST-QC_100uL-OxySplash_rep2of5_Fr1A=GPd5_Fr1E
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.00]


T: 1.56-1.60 AV: 3 NL: 5.27E1
























EY_191029_100uL-Cambridge-CSF-pool_20... 10/29/19 21:38:19
100uL Cambridge Pooled CSF (2019) + 20uL OxysterolSPLASH + 1ng 22S-I
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-HYD
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-590.0


rified)

A=GPd5_Fr1B=GPd0_s2_neat_07 #425 RT: 1.87 AV: 1 NL: 3.01E2



EY_191029_100uL-Cambridge-CSF-pool_20... 10/29/19 21:38:19
100uL Cambridge Pooled CSF (2019) + 20uL OxysterolSPLASH + 1ng 22
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-H
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-59


certified)
r1A=GPd5_fr1B=GPd0_s2_neat_07 #700 RT: 3.11 AV: 1 NL: 1.34E3



EY_191029_100uL-Cambridge-CSF-pool_20... 10/29/19 21:38:19
100uL Cambridge Pooled CSF (2019) + 20uL OxySPLASH + 1ng 22
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-H
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-59

certified)

r1A=GPd5_r1B=GPd0_s2_neat_07 #845 RT: 3.76 AV: 1 NL: 2.89E2



EY_191029_100uL-Cambridge-CSF-pool_20... 10/29/19 21:38:19
100uL Cambridge Pooled CSF (2019) + 20uL OxySPLASH + 1ng 22
EY_191029_100uL-Cambridge-CSF-pool_20uL-OxySPLASH_r2_NON-H
F: ITMS + c ESI Full ms3 585.41@cid30.00 501.33@cid35.00 [135.00-59

certified)
r1A=GPd5_Fr1B=GPd0_s2_neat_07 #540 RT: 2.39 AV: 1 NL: 3.45E3

